Adalimumab
Treatment for Psoriasis
Typical Dosage: 80mg SC at week 0, then 40mg SC every other week starting week 1
Effectiveness
75%
Safety Score
52%
Clinical Trials
175
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
52
DangerousModerateSafe
Treatment Details
Dosage Range
80mg SC at week 0, then 40mg SC every other week starting week 1
Time to Effect
4-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2.5(Treat 2.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
85(Treat 85 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$60,000
Monitoring:$600
Side Effect Mgmt:$800
Total Annual:$61,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$100,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$86,479
Cost per Remission
$307,000
Adalimumab Outcomes
for Psoriasis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+71%
Remission Rate
+20%
Common Side Effects
Injection site reaction
+12.9%
Upper respiratory tract infection
+12.3%
Headache
+8.7%
Rash
+5.5%
Active Clinical Trials
1 active trial recruiting for Adalimumab in Psoriasis
Evaluation of IL 12B Genetic Polymorphism (rs3213094)
NCT07128472RECRUITINGNA
40 participants
INTERVENTIONAL
Qina, Egypt
Started: Aug 1, 2025
Completed Clinical Trials
17 completed trials for Adalimumab in Psoriasis
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
NCT01970488COMPLETEDPHASE3
350 participants
INTERVENTIONAL
Saint Leonards, Australia +2 more
Started: Oct 18, 2013
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
NCT05073315COMPLETEDPHASE3
425 participants
INTERVENTIONAL
Birmingham, United States +87 more
Started: Oct 4, 2021
Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis
NCT02762955COMPLETEDPHASE3
344 participants
INTERVENTIONAL
Saint Petersburg, Russia
Started: Dec 1, 2016
Adalimumab in Adult Japanese Subjects With Psoriasis
NCT00647400COMPLETEDPHASE2, PHASE3
147 participants
INTERVENTIONAL
Bunkyō City, Japan +63 more
Started: Apr 1, 2006
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00646191COMPLETEDPHASE2
137 participants
INTERVENTIONAL
Started: Mar 1, 2003
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
NCT02581345COMPLETEDPHASE3
572 participants
INTERVENTIONAL
Beverly Hills, United States +89 more
Started: Sep 1, 2015
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis
NCT01387815COMPLETED
662 participants
OBSERVATIONAL
Calgary, Canada +35 more
Started: Aug 16, 2011
Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
NCT01265823COMPLETEDPHASE4
150 participants
INTERVENTIONAL
Circuito Comercial Satelite, Mexico +7 more
Started: Oct 1, 2010
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645814COMPLETEDPHASE2
148 participants
INTERVENTIONAL
Started: Mar 1, 2003
Adalimumab Biosimilar in Clinical Practice
NCT04808739COMPLETED
604 participants
OBSERVATIONAL
Barcelona, Spain
Started: Jun 1, 2020
A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
NCT00513370COMPLETEDPHASE3
203 participants
INTERVENTIONAL
Calgary, Canada +26 more
Started: Sep 1, 2007
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
NCT03210259COMPLETEDPHASE3
259 participants
INTERVENTIONAL
Birmingham, United States +48 more
Started: Jul 10, 2017
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00195676COMPLETEDPHASE3
1.47K participants
INTERVENTIONAL
Birmingham, United States +103 more
Started: May 1, 2004
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02850965COMPLETEDPHASE3
318 participants
INTERVENTIONAL
Anniston, United States +53 more
Started: Aug 17, 2016
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00237887COMPLETEDPHASE3
1.21K participants
INTERVENTIONAL
Started: Dec 1, 2004
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
NCT02660580COMPLETEDPHASE3
443 participants
INTERVENTIONAL
San Luis Obispo, United States +75 more
Started: Feb 16, 2016
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT05510063COMPLETEDPHASE4
371 participants
INTERVENTIONAL
Dupnitsa, Bulgaria +22 more
Started: Aug 4, 2022
Showing 20 of 175 total trials